slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 66,211-66,240
Pages 3,679
Rows per page 30
Component
66,211-66,240 of 110,355
04
Includes a specific date reference at the bottom: October 25, 2022.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · Situation & Context1 hit
05
Uses a two-column layout to contrast 'Significant Burden' with 'Urgent Need for Innovation'.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
The slide uses a horizontal arrow timeline to organize clinical trial phases and results.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · AgitationLoop · Cost Of Inaction1 hit
11
The slide uses chemical structure diagrams to illustrate the relationship between the racemate and its enantiomers.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
Data source: Zanos et al., 2016. The charts show dose-dependent reduction in immobility time.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
The slide uses a third-party study (Yang et al., 2015) to support the claim of a superior therapeutic index for R-ketamine.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
The slide contrasts the therapeutic benefit (MADRS) with the lack of side effects (CADSS) compared to S-Ketamine benchmarks.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
The slide uses a standard clinical trial flow diagram (randomization to treatment arms).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The slide uses a comparison structure to contrast safety/tolerability goals against efficacy goals.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
The slide outlines the study arms, randomization ratios, and primary endpoint timing for two distinct clinical trials.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
25
The chart displays statistical significance markers (p-values) at Day 1, Day 2, and Day 7.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
28
The chart shows a non-inferiority test using the Hamilton Anxiety Rating Scale (Ham-A).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
29
Slide 29 of the presentation.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
30
Slide 30. Includes statistical significance markers (*, **, ***).ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
35
The slide uses a grouped bar chart to show T-scores across three cognitive tests (HVLT, Symbol Coding, Category Fluency) for four dosage groups.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
36
Includes study design diagram and assessment schedule table.ATAI | Investor Presentation Deck | 41 slides · atai Life Sciences
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
01
Includes company logo, date, and corporate tagline.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
03
The slide uses a bulleted list to summarize clinical trial milestones and data-driven decision-making.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
05
The chart shows a significant p-value of 0.018 for NfL reduction. The study design is noted as randomized, double-blind, placebo-controlled, and parallel-group.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
06
The slide uses a process-flow style table to outline the clinical trial structure.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
07
The slide uses a list format to show progress/process steps.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
08
The framework is a clinical trial decision matrix based on ADAS-Cog11 and ADCS-ADL23 scores.Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
09
Athira Pharma | Results Presentation Deck | 11 slidesAthira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
10
Athira Pharma | Results Presentation Deck | 11 slidesAthira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
The slide uses a grid of metrics to establish the market size and the problem (lack of new treatments).Athira Pharma | Results Presentation Deck | 11 slides · Athira Pharma
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
04
The slide features a high-quality illustration of neurons, emphasizing the CNS focus of the company.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
05
The slide uses a simple additive equation visual to represent the growth of the company's CNS portfolio.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank 1 hit
09
Includes a scientific diagram of the GABAa receptor complex.Avenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · Solution1 hit
11
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit
12
Avenue Therapeutics | IPO Presentation Deck | 30 slidesAvenue Therapeutics | IPO Presentation Deck | 30 slides · Avenue Therapeutics
Regulatory filing Investment bank Beat · ProblemLoop · Cost Of Inaction1 hit